BioChain Institute Extends Spatial Multiomics Services
BioChain has reached partnerships with NanoString and 10x Genomics to extend its spatial multiomics services.
BioChain Institute, a supplier of biosample products and services, recently announced the extension of its spatial multiomics services via partnerships with NanoString Technologies and 10X Genomics. NanoString is a biotechnology company specializing in technology and translational research solutions, while 10X Genomics is a biotechnology company focused on gene sequencing technology.
According to an April 18, 2023 press release, spatial profiling is a technique that reveals the spatial context of RNA and proteins in tissue. BioChain spatial profiling technology uses a three-step process: selecting tissue samples, working with spatial biology scientists to determine which spatial path to use, and running the customized spatial process.
“Our partnerships, combined with our in-house services, make us a full-service provider of spatial biology services,” said Vidyodhaya Sundaram, vice-president of Business Development, BioChain, in the release. “With the technologies now available from BioChain, you can spatially resolve the entire transcriptome or high-plex protein across your tissue sample.”
“Our technology’s advantages include its high multiplexing ability, low hands-on time, and a straightforward procedure,” continued Sundaram. “Our goal is to bring this specialized technology to any researcher or biomedical professional who wants to use it.”
Source: BioChain Institute
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
